RT Journal Article
SR Electronic
T1 Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.27.20182238
DO 10.1101/2020.08.27.20182238
A1 Parkinson, Nicholas
A1 Rodgers, Natasha
A1 Fourman, Max Head
A1 Wang, Bo
A1 Zechner, Marie
A1 Swets, Maaike C.
A1 Millar, Jonathan E.
A1 Law, Andy
A1 Russell, Clark D.
A1 Baillie, J. Kenneth
A1 Clohisey, Sara
YR 2020
UL http://medrxiv.org/content/early/2020/09/27/2020.08.27.20182238.abstract
AB The increasing body of literature describing the role of host factors in COVID-19 pathogenesis demonstrates the need to combine diverse, multi-omic data to evaluate and substantiate the most robust evidence and inform development of therapies.Here we present a dynamic ranking of host genes implicated in human betacoronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses). Researchers can search and review the ranked genes and the contribution of different experimental methods to gene rank at https://baillielab.net/maic/covid19.We conducted an extensive systematic review of experiments identifying potential host factors. Gene lists from diverse sources were integrated using Meta-Analysis by Information Content (MAIC). This previously described algorithm uses data-driven gene list weightings to produce a comprehensive ranked list of implicated host genes.From 32 datasets, the top ranked gene was PPIA, encoding cyclophilin A, a drug-gable target using cyclosporine.Other highly-ranked genes included proposed prognostic factors (CXCL10, CD4, CD3E) and investigational therapeutic targets (IL1A) for COVID-19. Gene rankings also inform the interpretation of COVID-19 GWAS results, implicating FYCO1 over other nearby genes in a disease-associated locus on chromosome 3.As new data are published we will regularly update list of genes as a resource to inform and prioritise future studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to acknowledge funding from the following sources: BBSRC, Wellcome Trust, MRC, Sepsis Research (FEAT) and the Intensive Care SocietyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the referenced papers or by contacting authors of the referenced papers. https://baillielab.net/maic/covid19